PEB pacific edge limited

Ann: GENERAL: PEB: Pacific Edge issued patent in Europe for gastric cancer

  1. lightbulb Created with Sketch. 2
    • Release Date: 24/02/15 15:43
    • Summary: GENERAL: PEB: Pacific Edge issued patent in Europe for gastric cancer
    • Price Sensitive: No
    • Download Document  5.34KB
    					PEB
    24/02/2015 15:43
    GENERAL
    PRICE SENSITIVE
    REL: 1543 HRS Pacific Edge Limited
    
    GENERAL: PEB: Pacific Edge issued patent in Europe for gastric cancer
    
    24 February 2015
    
    Pacific Edge issued patent in Europe for gastric cancer
    
    Pacific Edge Limited (the Company) has extended the patent footprint for its
    stomach cancer technology after it was granted patent protection in Europe
    for 'Detection of Gastric Cancer'. Gastric or stomach cancer is one of the
    most common cancers in the world and Pacific Edge also has patents for its
    gastric cancer technology in New Zealand, Australia and China.
    
    Pacific Edge Chief Executive Officer David Darling says: "There is an
    estimated 934,000 new cases of gastric cancer diagnosed globally each year.
    While the greatest incidences occur in China, Japan and Korea, it is still a
    major health issue in Europe."
    
    "Investment in intellectual property is an important investment for Pacific
    Edge as it underpins the commercial capability of the company's products."
    
    While Pacific Edge would explore commercialisation opportunities for its
    gastric technology and continue to develop this towards a commercial product,
    its key focus remains on its Cxbladder products already in the market and the
    successful launch and further commercial development of the suite of
    Cxbladder products for detecting and managing bladder cancer.
    
    Pacific Edge was founded to use the latest developments in molecular biology
    to provide actionable diagnostic and prognostic tests that can contribute to
    a clinically meaningful difference in detection and management of cancer. "It
    is the driving force of our research and product development programs. We are
    now a fully-fledged cancer diagnostics company offering commercial products
    in New Zealand, Australia and the USA," David Darling says.
    
    For further information please contact
    David Darling
    Chief Executive Officer
    Pacific Edge Limited
    P: +64 (3) 479 5800
    
    ABOUT PACIFIC EDGE
    Pacific Edge Limited (NZX: PEB) is a New Zealand based cancer diagnostic
    company specialising in the discovery and commercialisation of diagnostic and
    prognostic technology for the early detection and monitoring of cancer.
    Products in development and in clinical trials are accurate and simple to use
    genomic and proteomic tools for the earlier detection, improved
    characterisation and better management of gastric, bladder, colorectal
    cancers and melanoma. The Company has recently completed and released its
    first product for the detection of bladder cancer, Cxbladder, and is actively
    marketing the product to urologists in New Zealand, Australia and soon to be
    Spain and the USA.
    
    www.pacificedge.co.nz
    ABOUT PACIFIC EDGE DIAGNOSTICS
    Pacific Edge takes its exciting cancer detection tests to market through its
    wholly owned subsidiaries, Pacific Edge Diagnostics NZ Limited and Pacific
    Edge Diagnostics USA Limited, and selected commercial partners in Australia
    and Spain, Healthscope Pathology and Oryzon respectively.
    
    www.pacificedgedx.com
    
    ABOUT Cxbladder
    Cxbladder is a non-invasive, accurate test that enables the early detection
    of bladder cancer from a small volume of urine. It provides general
    practitioners and urologists with a quick, cost effective and accurate
    measure of the presence of the cancer and provides urologists with the
    opportunity to reduce their reliance on the need for invasive tests such as
    cystoscopy. The recently published, Journal of Urology in September 2012,
    multi-centre international clinical study recruited 485 patients from
    Australia and New Zealand. Results show that Cxbladder out-performed all
    other benchmark technologies in the clinical trial and detected nearly all of
    the tumours of concern to a urologist; At 85% specificity the test sees 100%
    of T1, T2, T3, Tis and greater than 95% of high grade tumours.
    
    www.cxbladder.com
    ABOUT BLADDER CANCER
    Globally, bladder cancer has the 9th highest incidence and the 4th highest
    incidence for men. One of the early symptoms of bladder cancer is the
    presence of blood in the urine, haematuria. People with haematuria often
    present to their general practitioner before being referred on to a
    urologist.
    
    There are a number of 'at risk' occupations that have shown a much higher
    incidence of bladder cancer. Fire fighters and fire control officers have
    shown in a US study to have a twice the incidence of bladder cancer over non
    fire fighters. Smoking is a significant contributing factor (over 50% in
    males and 33% in females, and approximately one of every two new incidences
    of bladder cancer is linked to smoking).  Exposure to certain industrial
    chemicals or carcinogens increases risks for some occupations e.g.
    hairdressers, painters, printers, fire fighters and metal workers and
    chemical engineers. Incidence increases with age so the older you are, the
    greater the potential for bladder cancer.
    
    Bladder cancer has a very high recurrence rate of approximately 50%-70% with
    up to 30% of these recurring as later stage tumours. This is a higher
    recurrence than for skin cancer!  However, bladder cancers are highly
    treatable, especially if detected in the early stages. If diagnosed early
    there is a much higher probability of survival for early stage tumours
    relative to later stage tumours. This makes timely and regular surveillance
    and monitoring of this cancer a key element of the clinical process and of
    the individual's annual healthcare plan.
    End CA:00261058 For:PEB    Type:GENERAL    Time:2015-02-24 15:43:03
    				
 
Add to My Watchlist
What is My Watchlist?
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)
Last
10.4¢
Change
0.002(1.96%)
Mkt cap ! n/a
Open High Low Value Volume
10.4¢ 10.6¢ 10.4¢ $20.03K 191.3K

Buyers (Bids)

No. Vol. Price($)
0 962 10.4¢
 

Sellers (Offers)

Price($) Vol. No.
10.5¢ 10802 0
Last trade - 12.44pm 08/08/2025 (20 minute delay) ?
PEB (NZSX) Chart
arrow-down-2 Created with Sketch. arrow-down-2 Created with Sketch.